Actualités Antibe Therapeutics Inc - ATE | Actions Toronto Stock Exchange

Discussions et idées de trading en temps réel : négociez en toute confiance avec notre puissante plateforme.

Antibe Completes First Clinical Study of Otenaproxesul’s New Formulation

- All treatments well tolerated with no adverse safety signals - No elevations in liver enzymes Antibe Therapeutics Inc. (TSX: ATE, OTCQX:...

Antibe Initiates First Clinical Study of Otenaproxesul’s New Formulation

- Data in November will inform Phase II trial expected to launch next quarter Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical-stage...

Antibe Receives Approval to Initiate PK/PD Study of Otenaproxesul

Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical-stage company leveraging its hydrogen sulfide platform to develop next-generation...

Antibe Announces Results of 2023 Annual Meeting

Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical-stage company leveraging its hydrogen sulfide platform to develop next-generation...

Toronto Stock Exchange, Antibe Therapeutics Inc., View From The C-Suite

Toronto Stock Exchange, Antibe Therapeutics Inc., View From The C-Suite PR Newswire TORONTO, Aug. 21, 2023 TORONTO, Aug. 21, 2023 /PRNewswire/...

Antibe Reports Q1 2024 Interim Financial and Operating Results

- Otenaproxesul new formulation tablets manufactured for upcoming PK/PD study - PK/PD study results expected next quarter with Phase II...

Antibe Reports 2023 Year-End Results and Business Highlights

- Completed transition to otenaproxesul’s new formulation; tablet manufacturing underway - PK/PD study results expected in calendar Q4 2023 with...

Antibe’s Chief Medical Officer to Present at the 2023 Precision in Clinical Trials Summit

Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical-stage company leveraging its hydrogen sulfide platform to develop next-generation...

Antibe to Present at the 2023 Bloom Burton & Co. Healthcare Investor Conference

Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical-stage company leveraging its hydrogen sulfide platform to develop next-generation...

Antibe Provides April 2023 Corporate Update

Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical-stage company leveraging its hydrogen sulfide platform to develop next-generation...

ALTEN Acquires QA Consultants, Bringing Independent Software Quality Engineering Capabilities to its Services Portfolio

Global engineering and IT services giant adds award-winning North American software testing and quality engineering solutions provider to...

Antibe Reports Q3 2023 Interim Financial and Operating Results

- Recent animal data on otenaproxesul's new formulation confirm rapid drug uptake and potential for effective pain management - Targeting first...

Antibe Reports Q3 2023 Interim Financial and Operating Results

- Recent animal data on otenaproxesul's new formulation confirm rapid drug uptake and potential for effective pain management - Targeting first...

Antibe Reports Q2 2023 Interim Financial and Operating Results

- Progress includes otenaproxesul’s new formulation, strengthened IP and robust third-party sales projections - Sale of Citagenix subsidiary...

Antibe Closes Previously Announced Strategic Sale of Citagenix Subsidiary

Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical-stage company leveraging its hydrogen sulfide platform to develop next-generation...

Forums

Afficher les forums

Aucune Discussion Trouvée

Ajouter une Discussion

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Antibe Therapeutics Inc (ATE)

Discussions et idées de trading en temps réel : négociez en toute confiance avec notre puissante plateforme.

ATE Actualités

Antibe Completes First Clinical Study of Otenaproxesul’s New Formulation

Antibe Initiates First Clinical Study of Otenaproxesul’s New Formulation

Antibe Receives Approval to Initiate PK/PD Study of Otenaproxesul

Antibe Announces Results of 2023 Annual Meeting

Toronto Stock Exchange, Antibe Therapeutics Inc., View From The C-Suite

Antibe Reports Q1 2024 Interim Financial and Operating Results

Antibe Reports 2023 Year-End Results and Business Highlights

Antibe’s Chief Medical Officer to Present at the 2023 Precision in Clinical Trials Summit

Antibe to Present at the 2023 Bloom Burton & Co. Healthcare Investor Conference

Antibe Provides April 2023 Corporate Update

ALTEN Acquires QA Consultants, Bringing Independent Software Quality Engineering Capabilities to its Services Portfolio

Antibe Reports Q3 2023 Interim Financial and Operating Results

Antibe Reports Q3 2023 Interim Financial and Operating Results

Antibe Reports Q2 2023 Interim Financial and Operating Results

Antibe Closes Previously Announced Strategic Sale of Citagenix Subsidiary

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Antibe Therapeutics Inc (ATE) Actualités

Antibe Therapeutics Inc (ATE)

Discussions et idées de trading en temps réel : négociez en toute confiance avec notre puissante plateforme.

ATE Actualités

Antibe Completes First Clinical Study of Otenaproxesul’s New Formulation

Antibe Initiates First Clinical Study of Otenaproxesul’s New Formulation

Antibe Receives Approval to Initiate PK/PD Study of Otenaproxesul

Antibe Announces Results of 2023 Annual Meeting

Toronto Stock Exchange, Antibe Therapeutics Inc., View From The C-Suite

Antibe Reports Q1 2024 Interim Financial and Operating Results

Antibe Reports 2023 Year-End Results and Business Highlights

Antibe’s Chief Medical Officer to Present at the 2023 Precision in Clinical Trials Summit

Antibe to Present at the 2023 Bloom Burton & Co. Healthcare Investor Conference

Antibe Provides April 2023 Corporate Update

ALTEN Acquires QA Consultants, Bringing Independent Software Quality Engineering Capabilities to its Services Portfolio

Antibe Reports Q3 2023 Interim Financial and Operating Results

Antibe Reports Q3 2023 Interim Financial and Operating Results

Antibe Reports Q2 2023 Interim Financial and Operating Results

Antibe Closes Previously Announced Strategic Sale of Citagenix Subsidiary

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application